RedHill Biopharma Ltd. (RDHL) said that the United States Patent and Trademark Office or USPTO has granted new method of use patent that protects the administration of opaganib for the inhibition of a disease caused by a coronavirus in a subgroup population of patients requiring a fraction of inspired oxygen or FiO2 up to and including 60% at baseline.
The new patent, expiring in 2041, titled "Sphingosine Kinase 2 Inhibitor for Treating Coronavirus Infection in Moderately Severe Patients with Pneumonia", protects the results from a post-hoc analysis from the global Phase 2/3 study in hospitalized patients with COVID-19 pneumonia.
The analysis of 251 study participants requiring a FiO2 up to and including 60% at baseline (54% of study participants) demonstrated that treatment with oral opaganib resulted in a 62% reduction in mortality, improved outcomes in time to room air and median time to hospital discharge, and a reduced likelihood of intubation and mechanical ventilation in this large group of hospitalized, moderately severe COVID-19 patients.
For More Such Health News, visit rttnews.com
For comments and feedback contact: editorial@rttnews.com
Business News